Boehringer Ingelheim enrolls 1st patient in Phase 3 InPedILD™ trial
Category: #health  By Saipriya Iyer  Date: 2020-08-14
  • sharesocial_share_icon
  • Twitter
  • Facebook
  • LinkedIn

Boehringer Ingelheim enrolls 1st patient in Phase 3 InPedILD™ trial

Boehringer Ingelheim, a pharmaceutical company, has recently announced the enrollment of 1st patient in its Phase 3 InPedILD™ trial. The trial will evaluate the dose and safety profile of nintedanib among children and adolescents between 6-17 years of age, who are diagnosed with clinically significant fibrosing ILD (interstitial lung disease).

chILD (childhood ILD) includes over 200 rare respiratory disorders that affect adolescents, children, as well as infants, causing them difficulty in breathing. These patients also have high chances of developing lung fibrosis in some cases. Due to the high mortality and morbidity of the disease, it poses adverse impacts in their daily life. Currently, there are no approved therapies to treat chILD.

According to the Director of Breathing Institute at Children's Hospital Colorado, Prof. Robin Deterding, M.D., children with interstitial lung disease are likely to develop serious lung fibrosis that progresses. The company is targeting to identify the efficient treatment options for chILD, despite differences in the underlying causes of pulmonary fibrosis in children as compared to adults.

Marketed as Ofev®, nintedanib has been approved in over 80 countries for use in the treatment of people with IPF (idiopathic pulmonary fibrosis). Moreover, it has been approved in over 40 countries as the 1st and only therapy available to slow the decline rate of pulmonary function in SSc-ILD (systemic sclerosis-associated ILD) patients. It also has recently gained approval in the EU, Argentina, Brazil, Japan, Canada, and the U.S. for a 3rd indication to treat the chronic fibrosing ILDs patients with progressive phenotype.

Boehringer Ingelheim’s Associate Head of Medicine Pulmonology, Dr. Susanne Stowasser, has cited that the company is excited to commence the Phase 3 trial and offer valuable insights by examining the potential treatment of this progressive disease with rare and heterogeneous conditions, which currently has no efficient treatment options. The trial demonstrates the company’s high commitment in addressing the unmet needs and advancing the research activities to substantially cater to these patients suffering from pulmonary fibrosis.

Source credit:

https://www.businesswire.com/news/home/20200812005420/en/Phase-III-InPedILD%E2%84%A2-trial-enrolls-patient-evaluate



About Author

Saipriya Iyer

Email: [email protected]   linkdin twitter

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

More News By Saipriya Iyer

 Tabletop Tape Dispensers  market valuation to surge at healthy CAGR through 2026

Tabletop Tape Dispensers market valuation to surge at healthy CAGR through 2026

By Saipriya Iyer

A comprehensive research study on Tabletop Tape Dispensers market added by Market Study Report provides insights into the market size and growth trends of this industry over the forecast timeline. The study evaluates key aspects of Tabletop Tape D...

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

APAC, Europe, America region to generate massive revenues for General Well-Being Dietary Supplements market by 2026

By Saipriya Iyer

MarketStudyReport.com presents latest report on global General Well-Being Dietary Supplements Market, which evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The re...

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

Eugenia Jambolana Extract Market to Increase Exponentially During 2027

By Saipriya Iyer

The report Eugenia Jambolana Extract market provides high-quality information regarding the major market trends, product types and their application scope, competitive landscape, and impact of COVID-19 outbreak.

.

Request a...